In her role, Garlikov will serve as a member of the point-of-need molecular diagnostic developer’s executive team and will be responsible for driving commercial strategy for the decentralized diagnostics platform.
Garlikov will report to Bryan Dechairo, who serves as president and CEO of the Watertown, Massachusetts-based company, according to a news release.
She joins Sherlock with more than 20 years of sales and marketing experience, having held roles at Grail, Rodan + Fields, PepsiCo, Johnson & Johnson and Procter & Gamble. At Grail, she was VP of marketing where she helped define the market for the first multi-cancer early detection blood screening test, Sherlock said.
Garlikov has played a role in positioning the company for its next stage of growth from an R&D organization to a commercial competitor. Her experience includes scaling brands through a disciplined approach to marketing, sales, product development and commercialization to drive long-term growth.
“Sherlock has a tremendous opportunity to truly transform the way in which the healthcare industry operates, and I am excited to help lead the charge in making it a commercial diagnostic leader,” Garlikov said in the release. “Through Sherlock’s decentralized diagnostic platform, we can provide testing that can be used in virtually any setting without complex instrumentation, making it well suited for use both in the home and low-resource settings. By providing people access to answers to their health wherever and whenever it is needed, Sherlock is giving consumers control so they can have an easier path to treatment.
“I look forward to partnering with the exceptional team at Sherlock to bring our platform to the market and making this vision a reality for people around the world.”
Garlikov joins Sherlock a few months after the company completed an $80 million Series B financing round.
“Following our incredibly successful Series B funding round, we continue to advance the development of our novel diagnostic products and are committed to commercializing our proprietary platform to ignite a convenience revolution in healthcare,” Dechairo said. “Julie brings tremendous experience in consumer product commercialization, successfully launching a myriad of products and accelerating growth for digital consumer health and wellness brands.
“As a critical voice on our executive leadership team, Julie will play a vital role in scaling Sherlock on our aggressive path to commercialization.”
